Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
A legfontosabb adatok
- Ki végzi
- Innovent Biologics (Suzhou) Co. Ltd.
- Hol
- Shanghai (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 160 fő, tervezett
- Kezdés
- 2026. ápr. 18.
- Várható befejezés
- 2028. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- placebo
- Baricitinib tablets
- IBI3013
- A regiszteradat frissítve
- 2026. április 28.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for healthy adults in Part 1. Part 2 is for men with active non-segmental vitiligo or severe alopecia areata (patchy hair loss).
- Életkor
- Part 1 healthy volunteers: 18-45 years. Part 2 vitiligo: 18-65 years. Part 2 alopecia areata: 18-60 years.
- Nem
- Part 1: men and women. Part 2: men only.
- A betegség stádiuma
- Vitiligo: non-segmental type, diagnosed ≥3 months and <2 years ago. 3-50% of body skin affected, ≥0.5% of the face, at least 1 active patch. Alopecia areata: SALT ≥50% (AA-IGA grade 3-4), lasting ≥6 months and <4 years, no natural improvement in the past 6 months. Healthy volunteers: weight 50-120 kg (110–265 lb), BMI 17.0-28.0 kg/m2.
- Korábbi kezelés
- People with alopecia areata who took JAK inhibitor tablets without a good response cannot join. No live vaccines within 30 days before the start.
A részvétel fő kizáró okai
- Allergy to any part of IBI3013
- Past shingles, spread-out herpes, or repeated shingles
- Active tuberculosis now or before, or a positive tuberculosis blood test
- Pregnant or breastfeeding women
- Alopecia areata: recent heart attack, stroke, severe heart failure, or past deep vein blood clot
A regiszter feltételei, szó szerint
Mind a 25 feltétel megnézéseKevesebb
Ki vehet részt
- Part 1 - Healthy trial participants: Understand and voluntarily sign the informed consent form
- Part 1 - Healthy trial participants: Age between 18-45 years (inclusive), male or female
- Part 1 - Healthy trial participants: Weight between 50-120 kg (inclusive), and BMI between 17.0-28.0 kg/m2 (inclusive)
- Part 2 - Active non-segmental vitiligo trial participants: 18-65 years old (inclusive), male
- Part 2 - Active non-segmental vitiligo trial participants: Diagnosed with non-segmental vitiligo for ≥3 months and <2 years
- Part 2 - Active non-segmental vitiligo trial participants: Total affected BSA 3-50%, and facial affected BSA ≥ 0.5%; T-VASI 3-50 (inclusive), and F-VASI ≥0.5; ≥1 active lesion
- Part 2 - : Male participants of reproductive potential agree to use highly effective contraception and avoid sperm donation for 6 months after the last dose
- Part 2 - Severe alopecia areata trial participants: 18-60 years old (inclusive), male
- Part 2 - Severe alopecia areata trial participants: Meet the following severe alopecia areata criteria: a) SALT ≥50% (i.e., AA-IGA 3-4 grade) b) No spontaneous remission in the past 6 months (spontaneous remission defined as SALT reduction by ?10 points) c) Current duration of severe alopecia areata ≥6 months and <4 years
- All participants: Participants of reproductive potential agree to use highly effective contraception and avoid sperm or egg donation for 6 months after the last dose
Ki nem vehet részt
- All participants: History of live or attenuated live vaccine within 30 days prior to randomization, or expected to receive such vaccines during the study period until 3 months after the last dose of the investigational drug
- All participants: Donated blood or lost ≥400 mL of blood within 3 months before screening
- All participants: Received specific treatment within the time frame specified in the protocol, or participated in other investigational drug studies within the specified time
- All participants: Coexisting diseases at screening or previously, deemed unsuitable for clinical trials
- Active non-segmental vitiligo/Severe alopecia areata trial participants: Previous or coexisting diseases, which may affect the efficacy or safety evaluation of the study as assessed by the investigator
- Severe alopecia areata trial participants: Previously received oral JAK inhibitors with poor response; 16. Severe alopecia areata trial participants: Acute myocardial infarction, unstable ischemic heart disease, stroke, chronic heart failure (NYHA class III/IV) within 12 weeks prior to screening; or previous history of deep vein thrombosis, or high risk of deep vein thrombosis as assessed by the investigator; or severe neuropsychiatric disorder, deemed unsuitable for the study by the investigator
- All participants: Those who are allergic to any component of IBI3013
- All participants: History of herpes zoster or disseminated herpes simplex (single episode), or recurrent (more than one episode) localized herpes zoster
- All participants: Known history of active tuberculosis or clinical manifestations suggestive of tuberculosis, or positive interferon-gamma release assay unsuitable for participation
- All participants: History of drug abuse, drug dependence, or positive drug screening results during the screening period within 12 months
- Active non-segmental vitiligo trial participants: Coexisting segmental, undetermined type, or mixed-type vitiligo, or other skin pigmentation disorders, or other skin-related abnormalities that may affect the assessment of the study
- All participants: Abnormal vital signs, serum virology tests, laboratory tests, ECG, or other examinations with clinical significance, and deemed unsuitable for the study by the investigator
- All participants: Those who cannot tolerate subcutaneous injection
- All participants: Pregnant or lactating women
- Severe alopecia areata trial participants: Currently diagnosed with primary diffuse AA or ophiasis AA; or other types of hair loss that may interfere with AA evaluation
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 80 év között vagy?
Helyszínek itt: Kína
- Huashan Hospital, Fudan UniversityShanghai, KínaContact: Jing ZhangRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
A multicenter clinical study to evaluate the safety, PK characteristics, immunogenicity characteristics, and PD characteristics of IBI3013 in healthy trial participants and active non-segmental vitiligo trial participants and severe alopecia areata trial participants. The study is divided into 2 parts, with Part 1 involving healthy trial participants lasting up to 24 weeks, and Part 2 involving active non-segmental vitiligo trial participants and severe alopecia areata trial participants lasting up to 48 weeks.
A vizsgálat 3 csoportja
- Baricitinib tabletsMár használt kezelés, összehasonlításként
oral, 2mg, once daily
- placeboPlacebo, összehasonlításként
subcutaneous injection/intravenous infusion,single or multiple dosing
- IBI3013A vizsgált kezelés
subcutaneous injection/intravenous infusion,single or multiple dosing
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single-dose Administration of IBI3013 in Healthy Adult Trial Participants and Multiple-dose Administration in Active Non-segmental Vitiligo Trial Participants and Severe Alopecia Areata Trial Participants - a Randomized, Double-blind, Placebo-controlled, Dose-escalation Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07554222: ki vehet részt
- A regiszteradat frissítve
- 2026. április 28.